Pure Global AI
NCT05742802Recruiting

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations.
AstraZenecaPhase 3ClinicalTrials.govcombination product
Verified
Study focus
Disease/Condition
Chronic Obstructive Pulmonary Disease (COPD)
Drug/Device/Intervention
Tozorakimab
Study type
Interventional
Intervention type
combination product
Sponsor & location
Primary sponsor
AstraZeneca
Location
Sheffield,Lincoln,Newport Beach,Boynton Beach,Ormond Beach,Pensacola,Tampa,Evergreen Park,Normal,Kansas City,Bowling Green,Baton Rouge,Zachary,Missoula,Gastonia,Tulsa,Rock Hill,Houston,Caba,Melbourne,, Argentina,Australia,Belgium,Brazil,Bulgaria,Canada,Colombia,Czech,Denmark,Finland,Germany,Greece,Hun
Timeline & enrollment
Phase
Phase 3
Start date
Mar 06, 2023
End date
Aug 27, 2026
Enrollment
2544 participants
Primary outcome

Time to first severe COPD exacerbation in former smokers.

Summary

Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent
 for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3,
 extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with
 symptomatic COPD.

ICD-10 classifications
Other chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, unspecifiedOther specified chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease with acute exacerbation, unspecifiedChronic obstructive pulmonary disease with acute lower respiratory infection
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05742802
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05742802 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 2544 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.